Recombinant Newcastle disease virus Hemagglutinin-neuraminidase (HN)

What is the functional role of the Hemagglutinin-Neuraminidase (HN) protein in Newcastle disease virus infection?

The HN protein serves multiple critical functions during NDV infection. Primarily, it attaches the virus to sialic acid-containing cell receptors, thereby initiating the infection process. Upon binding to receptors, the HN protein undergoes a conformational change that enables the F protein to trigger fusion between viral and cell membranes. Additionally, the neuraminidase activity of HN ensures efficient virus spread by cleaving sialic acid from cellular glycoproteins, allowing mature virions to dissociate from infected cells .

Research methodologically demonstrates this dual functionality through:

• Binding assays that measure attachment to sialic acid-containing receptors

• Conformational studies showing structural changes upon receptor binding

• Enzymatic activity assays measuring neuraminidase function

The importance of these functions is evidenced by studies showing that changes in HN protein significantly affect tissue tropism. Chimeric viruses with HN proteins derived from virulent strains exhibit tissue predilection similar to the virulent viruses, while those with HN from avirulent strains show predilection patterns matching avirulent strains .

How can researchers differentiate between the hemagglutinating and neuraminidase activities of the HN protein experimentally?

Researchers can employ distinct methodological approaches to measure these separate activities:

For hemagglutination activity:

• Perform hemagglutination assays using two-fold serial dilutions of virus (typically starting at 10^7 TCID50/mL)

• Incubate with chicken erythrocytes in a V-bottom microtiter plate

• Observe and quantify the hemagglutination pattern after incubation

• Calculate the hemagglutination titer as the reciprocal of the highest dilution showing complete hemagglutination

For neuraminidase activity:

• Use a fluorometric assay with 2'-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid as substrate

• Prepare serial dilutions of virus samples

• Measure fluorescence at specific excitation/emission wavelengths after incubation

• Compare activities between different viral strains under standardized conditions

Research shows recombinant NDVs with HN modifications can exhibit significantly different hemagglutinating and neuraminidase activities compared to their parent strains. For example, extension of the HN protein has been shown to increase hemagglutination titer and receptor-binding ability while impairing neuraminidase activity .

How does length diversity in the HN protein affect NDV biological characteristics and pathogenicity?

Length diversity in the HN protein significantly influences biological activities but surprisingly does not alter virulence. Methodological approaches to investigate this include:

Experimental approach:

• Use reverse genetics to generate recombinant NDVs with truncated or extended HN proteins

• Evaluate virulence through mean death time and intracerebral pathogenicity indices

• Assess biological activities through multiple assays:

  • Hemagglutination titer measurement

  • Receptor-binding ability tests

  • Neuraminidase activity assays

  • Fusogenic activity evaluation

  • Replication ability assessment

Key research findings:
Research using genotype VII NDV (SG10 strain) demonstrated that different length mutations in the HN protein did not alter virulence, but significantly affected biological activities. C-terminal extension of the HN protein:

• Increased hemagglutination titer and receptor-binding ability

• Impaired neuraminidase activity

• Reduced fusogenic activity

• Decreased replication ability

These findings indicate that while the HN protein length diversity affects biological functionality and replication, it does not directly influence pathogenicity, suggesting other viral factors may play more significant roles in determining virulence.

What methodological approaches can be used to study the contribution of the HN gene to NDV pathogenesis?

Research on HN gene contribution to pathogenesis employs several sophisticated methodologies:

Reverse genetics approach:

• Exchange HN genes between virulent and avirulent NDV strains (e.g., between rBeaudette C and rLaSota)

• Generate chimeric viruses with specific HN gene modifications

• Assess resulting changes in:

  • Hemadsorption and neuraminidase activities

  • Fusion promotion capacity

  • Tissue tropism patterns

  • Virulence indices (ICPI, MDT)

Protein-level functional analysis:

• Express wild-type and modified HN proteins

• Evaluate hemadsorption, neuraminidase, and fusogenic promotion activities

• Compare protein-level activities with those observed at the viral level

In vivo pathogenesis studies:

• Infect experimental animals with parental and chimeric viruses

• Analyze tissue distribution and viral load in different organs

• Evaluate histopathological changes in tissues

• Measure cytokine responses and immune cell infiltration

Research findings show that the HN gene significantly influences tissue tropism patterns. Chimeric viruses with HN proteins from virulent strains exhibit tissue distribution similar to the virulent parental virus, indicating the HN protein is a determinant of tissue preference in NDV infection .

How does the expression of foreign proteins by recombinant NDV affect HN protein expression and function?

The expression of foreign proteins by recombinant NDV can lead to significant structural and functional alterations in the viral glycoproteins, including the HN protein. A methodological approach to investigate this includes:

Experimental design:

• Generate recombinant NDV expressing a foreign protein (e.g., H5 hemagglutinin)

• Use immunogold labeling to quantify glycoprotein expression on virion surfaces

• Perform comparative functional assays between parental and recombinant viruses

• Evaluate neutralization profiles using anti-F and anti-HN monoclonal antibodies

Research findings:
Studies comparing parental NDV LaSota and recombinant NDV-H5 demonstrated:

These findings indicate that expressing foreign proteins causes redistribution of viral glycoproteins on the virion surface, with rNDV-H5 showing higher levels of HN expression and corresponding increases in hemagglutinating and neuraminidase activities .

What are the key steps in constructing recombinant NDV expressing modified HN proteins using reverse genetics?

Construction of recombinant NDV with modified HN proteins involves a systematic molecular approach:

Methodological workflow:

• Genome modification:

  • Create restriction sites (e.g., XbaI) in noncoding regions of the NDV genome

  • This typically involves site-directed mutagenesis using PCR to introduce specific nucleotide substitutions

• cDNA construction:

  • Amplify targeted genome regions using PCR

  • Insert modified HN genes or foreign genes at the created restriction sites

  • Assemble the complete antigenomic cDNA with the desired modifications

• Virus recovery:

  • Transfect the antigenomic cDNA into permissive cells (e.g., HEp-2 cells)

  • Co-transfect with support plasmids expressing viral proteins (N, P, and L)

  • The support proteins initiate transcription and replication of the recombinant genome

• Virus propagation:

  • Propagate recovered viruses in embryonated eggs or cell cultures (e.g., DF-1 chicken fibroblast cells)

  • Confirm genetic modifications by sequencing

  • Verify protein expression through immunofluorescence or Western blotting

This approach allows researchers to precisely modify the HN protein or insert foreign genes into the NDV genome, enabling detailed studies of HN protein function and the development of recombinant vaccines.

What assays are recommended for evaluating the biological activities of modified HN proteins in recombinant NDV?

Several specialized assays are essential for comprehensive evaluation of HN protein biological activities:

Recommended methodological approaches:

• Hemagglutination assay:

  • Prepare two-fold serial dilutions of virus in PBS

  • Add chicken erythrocytes (typically 0.5-1%)

  • Incubate at room temperature or 4°C

  • Record highest dilution showing complete hemagglutination

• Neuraminidase activity assay:

  • Use substrate 2'-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid

  • Incubate with serial dilutions of virus

  • Measure fluorescence (excitation: ~360nm, emission: ~450nm)

  • Calculate relative activity compared to controls

• Cell fusion assay:

  • Infect cell monolayers with recombinant viruses

  • Observe for syncytia formation at different time points

  • Quantify fusion index (ratio of nuclei in syncytia to total nuclei)

  • Compare fusion promotion efficiency between viruses

• Hemadsorption assay:

  • Infect cell monolayers with viruses

  • Add erythrocytes and allow adsorption

  • Wash to remove unbound erythrocytes

  • Quantify bound erythrocytes through visual counting or hemoglobin measurement

• Virus replication kinetics:

  • Infect cells at standardized multiplicity of infection (MOI)

  • Collect samples at multiple time points

  • Determine viral titers using TCID50 or plaque assays

  • Plot growth curves for comparison

What potential risks need to be assessed when developing recombinant NDV-vectored vaccines?

Development of recombinant NDV-vectored vaccines requires systematic assessment of three major risk categories:

Risk of recombination:

• Methodological approach:

  • Perform co-infection studies with rNDV vectors and wild-type viruses

  • Use established cell culture protocols with products from egg-based studies

  • Monitor for emergence of recombinant viruses by genetic analysis

  • Assess whether inserted foreign genes (e.g., avian influenza HA) can recombine with wild-type viruses through homologous or non-homologous recombination

Risk of reversion to virulence:

• Methodological approach:

  • Create rNDV with attenuated HN or fusion (F) genes

  • Passage viruses in 14-day-old specific pathogen-free embryonated chicken eggs

  • Use cell culture systems that favor growth of virulent viruses

  • Sequence HN and F genes after passage to detect mutations

  • Test selected viruses in embryos and birds to define changes in virulence

Risk of spread to non-target species:

• Methodological approach:

  • Identify common wild avian species associated with poultry houses (e.g., pigeons, starlings, house sparrows)

  • Experimentally infect these species with rNDV and rNDV expressing foreign genes

  • Assess susceptibility to infection and potential for virus transmission

  • Evaluate whether the virus can change within these species

  • Test recovered viruses for virulence changes

These systematic risk assessments provide critical data to regulatory agencies regarding the safety of recombinant NDV-vectored vaccines for use in poultry.

How can researchers evaluate the immunogenicity of recombinant NDV expressing heterologous antigens?

Evaluating immunogenicity of recombinant NDV vaccines requires comprehensive methodological approaches:

In vitro immunogenicity assessment:

• Infect cell cultures with recombinant NDV

• Measure expression of heterologous antigens through:

  • Western blotting

  • Immunofluorescence microscopy

  • Flow cytometry

• Analyze innate immune sensing mechanisms:

  • Measure expression of pattern recognition receptors (PRRs) including TLR3, MDA5, and LGP2

  • Quantify type-I interferon responses

  • Evaluate the kinetics of immune activation

In vivo immunogenicity evaluation:

• Administer recombinant NDV to appropriate animal models:

  • Use phylogenetically relevant models like non-human primates

  • Consider route of administration (typically intranasal for respiratory pathogens)

  • Test different dosage levels

• Assess immune responses through:

  • Serum antibody titers against both NDV and the heterologous antigen

  • Mucosal antibody responses (IgA)

  • Cell-mediated immune responses (T-cell proliferation, cytokine production)

• Conduct challenge studies to assess protective efficacy

Research demonstrates that recombinant NDV can effectively express foreign viral proteins like HPIV3 HN protein and induce immune responses in non-human primates, providing a promising platform for vaccine development against multiple pathogens .

What are common challenges in recovering and propagating recombinant NDV, and how can researchers overcome them?

Researchers face several challenges when working with recombinant NDV systems that can be addressed through specific methodological approaches:

Challenge 1: Low transfection efficiency

• Solution: Optimize transfection conditions by:

  • Testing different transfection reagents specifically designed for RNA virus recovery

  • Adjusting DNA-to-transfection reagent ratios

  • Using highly permissive cell lines like HEp-2 cells

  • Co-transfecting optimal ratios of support plasmids expressing N, P, and L proteins

Challenge 2: Destabilization of viral genome by foreign inserts

• Solution: Implement strategic insertion approaches:

  • Identify optimal insertion sites (e.g., downstream noncoding regions of P gene)

  • Create specific restriction sites through carefully designed mutations

  • Consider the size limitations of foreign inserts

  • Ensure foreign genes follow the "rule of six" compatibility with NDV genome

Challenge 3: Loss of infectious virus during propagation

• Solution: Optimize propagation systems:

  • Use embryonated eggs for primary isolation and amplification

  • For cell culture propagation, select appropriate cell lines (e.g., DF-1 chicken fibroblast cells)

  • Supplement media with 2.5% fetal bovine serum to enhance stability

  • Harvest virus at optimal time points based on cytopathic effects

Challenge 4: Altered growth characteristics due to HN modifications

• Solution: Adapt propagation conditions:

  • Adjust incubation temperatures and times

  • Monitor viral replication through growth curve analysis

  • Implement adaptive passage to improve growth characteristics

  • Consider using helper viruses for difficult-to-recover constructs

These methodological approaches help overcome technical challenges in working with recombinant NDV systems and increase the likelihood of successful recovery and propagation of modified viruses.

How do modifications to the HN protein affect the structural properties of recombinant NDV particles?

Modifications to the HN protein can significantly alter virion structure and composition:

Methodological approach for structural analysis:

• Generate recombinant NDV with modified HN proteins

• Purify viral particles through ultracentrifugation

• Perform electron microscopy with immunogold labeling using:

  • Anti-HN monoclonal antibodies

  • Anti-F monoclonal antibodies

  • Antibodies against any inserted foreign proteins

• Quantify gold particles and normalize per virion surface unit

• Perform comparative analysis between parental and recombinant viruses

Research findings on structural changes:
Studies comparing NDV LaSota and recombinant NDV-H5 revealed significant structural differences:

These structural changes directly affect biological functions, with recombinant NDVs expressing foreign proteins showing higher hemagglutinating and neuraminidase activities but altered fusion capabilities and neutralization profiles .

The redistribution of surface glycoproteins also affects how these viruses interact with the immune system, particularly with pattern recognition receptors involved in innate immune sensing, which has significant implications for vaccine development and immunogenicity studies .